Program
Letrozole
Also written as “letrozole”, “Letrozole Tablets 2.5 mg” and “Arm C: Gedatolisib + Palbociclib + Letrozole”.
Its studies are mostly in Breast Neoplasms · Neoplasms · Polycystic Ovary Syndrome · Endometrial Neoplasms · Infertility, led by 7 companies.
Drug pageLetrozole: every studyMany companies study it; this page follows only the 38 they lead. All 340 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novartisits history only | 280 open or running | phase 4since Apr 10, 2001 | Apr 10, 2001 | none ahead |
| Dr. Reddy's Laboratoriesits history only | 20 open or running | phase 1since Jun 13, 2011 | Jun 13, 2011 | none ahead |
| Egymedicalpediaits history only | 21 open or running | phase 1since Apr 9, 2024 | Apr 9, 2024 | none ahead |
| Hikma Pharmaceuticals | 20 open or running | phase 1since Jun 3, 2011 | Jun 3, 2011 | none ahead |
| Viatrisits history only | 20 open or running | phase 1since Mar 30, 2008 | Mar 30, 2008 | none ahead |
| Rovi Pharmaceuticals Laboratoriesits history only | 10 open or running | phase 1since Jan 8, 2018 | Jan 8, 2018 | none ahead |
| Sun Pharmaceutical Industriesits history only | 10 open or running | phase 3since Jan 24, 2008 | Jan 24, 2008 | none ahead |
Also a collaborator on its studies: Gilead Sciences, Pfizer and Hoffmann-La Roche.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Hikma Pharmaceuticals only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 3, 2011First studies: 2 phase 1 studies in Breast NeoplasmsFirst studyNCT01367652, NCT01367626
TargetBeta
“Cytochrome P450 19A1 inhibitor”ChEMBL 37, by rule
Studies
All 2 Hikma Pharmaceuticals leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT01367652Breast Neoplasms · United States | 1 | Completed | Apr 2008 | 28 |
| NCT01367626Breast Neoplasms · United States | 1 | Completed | Apr 2008 | 28 |
How it is read
Names in the registry
- “Letrozole”, 40 entries
- “letrozole”, 6 entries
- “Letrozole Tablets 2.5 mg”, 2 entries
- “Arm C: Gedatolisib + Palbociclib + Letrozole”, 1 entry
- “PF-07104091 + PF-07220060 + letrozole dose expansion”, 1 entry
Conditions, from the studies’ own filings
- Breast Neoplasms, 37 studies
- Neoplasms, 2 studies
- Polycystic Ovary Syndrome, 2 studies
- Endometrial Neoplasms, 2 studies
- Infertility, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.